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Abstract
Background: A DNA methylation signature has been characterized that distinguishes rheumatoid arthritis (RA)
fibroblast like synoviocytes (FLS) from osteoarthritis (OA) FLS. The presence of epigenetic changes in long-term
cultured cells suggest that rheumatoid FLS imprinting might contribute to pathogenic behavior. To understand
how differentially methylated genes (DMGs) might participate in the pathogenesis of RA, we evaluated the stability
of the RA signature and whether DMGs are enriched in specific pathways and ontology categories.
Methods: To assess the RA methylation signatures the Illumina HumanMethylation450 chip was used to compare
methylation levels in RA, OA, and normal (NL) FLS at passage 3, 5, and 7. Then methylation frequencies at CpGs
within the signature were compared between passages. To assess the enrichment of DMGs in specific pathways,
DMGs were identified as genes that possess significantly differential methylated loci within their promoter regions.
These sets of DMGs were then compared to pathway and ontology databases to establish enrichment in specific
categories.
Results: Initial studies compared passage 3, 5, and 7 FLS from RA, OA, and NL. The patterns of differential
methylation of each individual FLS line were very similar regardless of passage number. Using the most robust
analysis, 20 out of 272 KEGG pathways and 43 out of 34,400 GO pathways were significantly altered for RA
compared with OA and NL FLS. Most interestingly, we found that the KEGG ‘Rheumatoid Arthritis’ pathway was
consistently the most significantly enriched with differentially methylated loci. Additional pathways involved with
innate immunity (Complement and Coagulation, Toll-like Receptors, NOD-like Receptors, and Cytosolic DNA-
sensing), cell adhesion (Focal Adhesion, Cell Adhesion Molecule), and cytokines (Cytokine-cytokine Receptor). Taken
together, KEGG and GO pathway analysis demonstrates non-random epigenetic imprinting of RA FLS.
Conclusions: The DNA methylation patterns include anomalies in key genes implicated in the pathogenesis of RA
and are stable for multiple cell passages. Persistent epigenetic alterations could contribute to the aggressive
phenotype of RA synoviocytes and identify potential therapeutic targets that could modulate the pathogenic
behavior.
Background
RA is a chronic inflammatory disease marked by syno-
vial hyperplasia and invasion into cartilage and bone.
This process is mediated, in part, by cytokines like IL-1,
IL-6, and TNF that activate a broad array of cell signal-
ing mechanisms and leads to the release of destructive
enzymes [1]. Fibroblast-like synoviocytes (FLS), which
form the inner lining of the synovium, play an active
role in joint destruction by invading intra-articular carti-
lage and other support structures of the joint [2]. These
mesenchymal cells normally produce hyaluronic acid
and other lubricants that facilitate joint movement and
a low friction environment.
FLS display an aggressive phenotype in RA that per-
sists in long-term culture [2,3]. These imprinted cells
can migrate between joints and exhibit characteristics of
locally invasive transformed cells [4]. The mechanism
that contribute to functional alterations in RA FLS are
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only partially understood and include somatic muta-
tions, alterations in cell survival and apoptosis genes,
and persistent activation of signaling pathways [3].
Epigenetic changes, including aberrant miRNA expres-
sion [5], can also contribute to the aggressive RA FLS
phenotype.
More recently, a characteristic DNA methylation sig-
nature that could affect cell function and distinguishes
RA from osteoarthritis (OA) FLS was discovered [6].
Differentially methylated loci (DML) involve many key
genes implicated in inflammation, immune responses,
cell-cell interactions, and matrix regulation. The original
study defining the RA methylation pattern was per-
formed on a relatively limited number of cell lines and
did not evaluate the stability of the signature over multi-
ple passages. For the present analysis, we increased the
number of OA and RA cell lines and included normal
(NL) synoviocytes. The greater number of cells per-
mitted a focused evaluation of promoter sequences and
a more detailed pathway analysis. The results demon-
strate a pattern of differentially methylated pathways in
RA FLS that define pathogenic processes that could per-
mit identification of novel therapeutic targets.
Methods
FLS and patient phenotype
FLS were isolated from synovial tissues obtained from
11 RA and 11 OA patients at the time of joint replace-
ment as described previously [7]. The diagnosis of RA
conformed to the American College of Rheumatology
1987 revised criteria [8]. The protocol was approved by
the UCSD Human Subjects Research Protection Pro-
gram. Synoviocytes were used from passage 3 through 7,
when FLS were a homogeneous population with < 1%
CD11b, < 1% phagocytic, and < 1% FcR II positive cells.
Normal human synoviocytes were provided by the San
Diego Tissue Bank from autopsy specimens. Preparation
of the genomic DNA from early, middle, and late pas-
sage cells (passages 3, 5, and 7, respectively) for the Infi-
nium HumanMethylation450 BeadChip (Illumina; San
Diego, CA) and calculation of methylation frequencies
(Beta values) was performed as previously reported [6].
The BeadChip data from the original 11 samples in
reference 6 are available through the Gene Expression
Omnibus (GEO) under the accession [GSE46364].
BeadChip processing and validation
BeadChip data were processed in R 2.15 using the methy-
lumi and minfi packages. Data were normalized via the
minfi package (preprocessIllumina function). CpGs with
detection P values > 0.001 were filtered out. For chip vali-
dation, biologic replicates within chips were performed
and demonstrated a mean correlation coefficient r2 =
0.9338. Replicates between chips demonstrated a mean
correlation coefficient r2 = 0.9858. Regarding potential
performance differences between Infinium I and II
probes on the BeadChip, we reasoned that since CpGs
were tested independently, probe type-specific bias
would be equally present in both phenotype populations.
Therefore, the risk of false-positive detection due to
probe-type differences is low.
Methylation heat maps and histograms
Methylation frequencies of previously identified RA-OA
differentially methylated CpGs [6] across FLS samples
were multiplied by 100 to obtain values interpreted as
methylation percentages. The Euclidian distances
between FLS samples and CpGs were calculated and
hierarchically clustered using complete linkage. The
results were visualized in a heat map using the heat-
map.2 function in the gplots R package as previously
described [6]. Missing values were represented with a
white color. For each FLS cell line, beta value differences
of the previously identified 1,859 CpG signature between
passages were calculated and plotted as histograms with
bins for every 0.01 interval. The bar areas were normal-
ized so that their total sum equaled unity.
Correlations between FLS passage number
The FLS lines were experimentally processed the same
day across three BeadChips. This approach minimized
intra-dataset (that is, KEGG and passage FLS datasets)
batch effects like BeadChip lot, reagent lot, lab proces-
sing, or temporal variability). The tight hierarchical clus-
tering of P5 FLS samples across the KEGG and passage
datasets demonstrates that inter-dataset batch effects are
minor relative to the RA methylation signature (see
Results). Furthermore, validation studies of duplicate
samples on the same BeadChip, on different BeadChips,
or performed on different runs showed very strong cor-
relations (data not shown). For each cell line, the Spear-
man Rank correlation of beta values of the previously
identified 1,859 CpG signatures was calculated across
passages. For each pairwise correlation calculation,
CpGs with missing data were omitted. For the correla-
tion between replicates of passage 5 comparisons were
made within the same cell line. To estimate passage cor-
relation, the Spearman correlation coefficients between
passage 5 and the other passages were calculated per
cell line. An average was calculated based on these cor-
relation coefficients.
Identifying differentially methylated genes (DMGs)
A Welch’s t-test was used to calculate the significance of
differential methylation. We chose to apply Welch’s t-test
as the samples may have unequal variance. All loci that
are present on the array were tested and the resulting P
values were converted into q values [9]. Additionally, the
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average difference in mean values at each position was
calculated. Loci with q values < 0.05 and average mean
differences > 0.1, or < -0.1, were labelled as differential
methylated loci (DML). Missing values and values with
detection P values > 0.01 were not included in this analy-
sis. At a specific locus, if values were absent but at least
three values present, for each of the two groups being
considered, then comparison was made between only the
existing values. If there were less than three values pre-
sent in a single group, at a specific locus, then this locus
was ignored from the analysis. The DMLs within the pro-
moters of genes were identified and the DMLs were
linked to the corresponding genes. The locations of
refseq genes were obtained from the University of Cali-
fornia, Santa Cruz. If a promoter contained one or more
DMLs within a 3 kb window around a gene’s transcrip-
tion start site (TSS) (-2500 bps to +500 bps from the
TSS) then the gene was labelled as a DMG.
The significance of DMG in 271 KEGG human path-
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The ‘total genes in the pathway’ and ‘total genes in
KEGG’ only considered genes that are present in a
KEGG pathway and are covered by the BeadChip.
The hypergeometric distribution was used to calculate
enrichment P values that were converted into q values.
Resulting q values represented the fraction of randomly
selected background gene sets that were at least as
enriched in genes found in the tested pathway as the
DMG set. A q value threshold of 0.05 determined signif-
icance. The significance of 34,449 GO categories was
tested in the same way. The background for the GO
analysis included all the genes whose promoters are cov-
ered by the methylation array and that are present in
the GO database.
Results
Stability of the methylome signature in RA FLS
We previously identified a methylome signature in RA
comprised of 1,859 DML and predicts the phenotype of
passage 5 FLS (RA vs. OA). One critical question to
answer before performing additional pathway analysis
with more cell lines is whether this signature is stable.
Therefore, we assayed the methylomes of nine FLS cell
lines (three RA, three OA, and three NL) at the 3rd,
5th, and 7th passage (P3, P5, and P7, respectively). Pas-
sage 3 cells were the earliest samples evaluated because
passage 1 and 2 lines can include other cell types. By
the 3rd passage, FLS are a homogeneous population of
cells (< 1% CD11b positive, < 1% phagocytic, and < 1%
FcR II and FcR III receptor positive) [2].
We first performed hierarchical clustering of RA, OA,
and NL samples from the three passages. In addition,
we included P5 samples from our previous study as an
internal biological sample control. The RA, OA, and NL
groups clustered separately at all passages, confirming
that the RA methylome signature is stable over many
passages (see Figure 1A for representative examples). Of
note, the replicates of P5 clustered very closely and were
also only slightly different from the other passages.
To further explore the stability of the RA methylome
signature over time, we considered the difference in
methylation percentages between different passages and
the replicates of P5. Figure 1B shows that variation
between replicates of P5 is comparable to the variation
between P5-P3 and P5-P7. The correlation across the
nine cell lines between P5 replicates is 0.950 while the
correlation between P3-P5 is 0.943. These data show
that P3 and P5 are as highly correlated as replicates of
the same passage and that there is very little change in
the methylation frequencies between P3 and P5. There
is a slight decrease in correlation between P3 to P7
(0.883) as the cells approach senescence.
Determination of differentially methylated genes in RA
FLS
Having confirmed that the RA methylome signature is
stable we then investigated its relationship with clinical
phenotype on a systems level. Previously, we had carried
out KEGG and GO analysis on a limited set of samples
(six RA and five OA FLS lines). We have advanced on
this previous analysis by increasing the sample size to
11 RA and 11 OA and adding six NL lines. The
increased number of samples from 11 to 28 allowed us
to focus on the subset of DMLs within the gene promo-
ters (-2500 to +500 bps from the TSS). DMLs were
identified by calculating P values using Welch’s t test.
Then the resulting P values were corrected for multiple
testing to produce q values. Genes that contain DMLs
within their promoters were labeled DMGs. An average
mean difference of 0.1 or greater was required for a
DML to be considered significant.
Identification of DMGs was carried out by comparing
the RA samples to five combinations of OA and NL:
‘RA vs. OA’, ‘RA vs. NL’, ‘RA vs. OA+NL’ (which com-
bines the OA and NL databases), ‘RA vs. OA or NL’
(which includes DMGs that are significant in either RA
vs. OA or RA vs. NL) and ‘RA vs. (OA or NL) or (OA
+NL)’ (denoted as ‘combined’). We focused on compari-
sons that take account of both OA and NL as these are
of greatest relevance to differentiating RA phenotype
from non-RA. Furthermore, smaller NL sample size
identified a reduced set of DMGs making this set of
DMGs unsuitable for systems level analysis.
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A summary of the number of genes identified in each
of the comparisons is shown in Table 1 (for a full list of
genes, see Supplemental Table 1). The majority (89%) of
the 2,375 total genes identified (the combined) as DMGs
were identified solely by comparison of RA and OA.
Determination of differentially methylated KEGG
pathways in RA FLS
Having established sets of DMGs, we identified the bio-
logical pathways and gene ontologies that were enriched
within the sets. To identify enriched pathways, the
DMGs where mapped to the KEGG pathways and GO
databases. Enrichment P values were then calculated
using the hypergeometric distribution. Then these P
values were corrected for multiple testing to produce q
values. A q values cut-off of < 0.05 was considered
significant.
A summary of the total number of significant KEGG
pathways and GO categories that were found significant
is given in Table 2. The 221 additional DMGs that are
included in the Combined set have a significant effect on
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Figure 1 The RA methylome signature is stable over passages. (A) Hierarchical clustering RA, OA, and NL samples at P3, P5, and P7. Each
column shows the methylation level at one of the 1,859 DML. Additionally, samples from P5 of Nakano et al. 2012 are shown as reference and
are labeled as rep. (B) The distribution of the difference in beta values between passages for RA sample.
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pathways identified as significantly enriched compared
with the previous published analysis on a limited dataset.
The enriched KEGG pathways out of a total of 271
pathways evaluated are summarized in Table 3 using the
various groupings described above. The top ranked
pathway is the KEGG ‘rheumatoid arthritis’ pathway
(see Figure 2) with 2.47-fold enrichment (P = 1.729e-05
and q = 0.0027) and 24 out of 89 genes identified as
DMGs in the union set. This confirms that the observed
alterations in DNA methylation are highly relevant to
RA. Furthermore, eight additional immunological path-
ways relevant to RA were also identified as significantly
enriched with DMGs in RA FLS. For example, KEGG
‘Complement and coagulation cascades’ pathway (see
Figure 3) is 1.99-fold enriched (P = 0.0064 and q =
0.0494) with 15 out of 69 genes labeled as DMGs in the
union set. The KEGG ‘Focal Adhesion’ pathway (see
Figure 4) is 1.61-fold enriched (P = 0.0027 and q =
0.0420) with 35 out of 199 genes labeled as DMGs in
the union set. The KEGG ‘Toll-like receptor signaling’
Table 1 A summary of the number of DMGs, pathways,
and GO terms identified as significant
Combined OA+NL OA or NL
DMGs 2,375 472 2,346
KEGG 20 19 25
GO 43 546 40
The sets were defined through the following comparisons: ‘combined’
combines the sets from the other two comparisons; ‘OA+NL’ compares RA
with a combined RA and NL database; ‘OA or NL’ includes DMGs that are
significant in either ‘RA vs. OA’ or ‘RA vs. NL’. A complete list of DMGs is
provided in Additional file 1. DMGs: differentially methylated genes.
Table 2 KEGG pathways that enriched with genes that contain DML within their promoters
Comparison name Combined OA+NL OA or NL
Comparison description RA vs (OA or NL) or (OA+NL) RA vs OA+NL RA vs OA or NL
Pathway name EF (q-value) # of DMGs (%) EF (q-value) # of DMGs (%) EF (q-value) # of DMGs (%)
Rheumatoid arthritis 2.5 (0.00266) 24 (27.0) 6.5 (1.91e-05) 12 (13.5) 2.3 (0.00467) 22 (24.7)
NOD-like receptor signaling pathway 2.5 (0.00741) 16 (27.6) 5.8 (0.0014) 7 (12.1) 2.3 (0.0374) 14 (24.1)
Cell adhesion molecules (CAMs) 1.8 (0.0294) 25 (19.4) 3.0 (0.0232) 8 (6.2) 1.8 (0.0343) 25 (19.4)
Focal adhesion 1.6 (0.0287) 35 (17.6) 1.6 (0.0321) 35 (17.6)
Cytosolic DNA-sensing pathway 4.6 (0.0202) 5 (9.6)
Cytokine-cytokine receptor interaction 2.3 (0.0231) 12 (4.8)
Toll-like receptor signaling pathway 1.9 (0.0377) 19 (20.7)
Complement and coagulation cascades 2.0 (0.0494) 15 (21.7)
Staphylococcus aureus infection 2.9 (0.00379) 16 (31.4) 4.7 (0.019) 5 (9.8) 2.9 (0.00457) 16 (31.4)
Graft-versus-host disease 2.7 (0.0211) 11 (29.7) 10.4 (2.66e-05) 8 (21.6) 2.5 (0.0468) 10 (27.0)
Allograft rejection 2.6 (0.031) 10 (28.6) 9.6 (0.000159) 7 (20.0) 2.7 (0.0389) 10 (28.6)
Leishmaniasis 2.0 (0.0451) 15 (22.1) 4.9 (0.00304) 7 (10.3) 2.1 (0.048) 15 (22.1)
Toxoplasmosis 1.7 (0.0435) 24 (18.8) 3.4 (0.00759) 9 (7.0) 1.7 (0.046) 24 (18.8)
Viral myocarditis 2.6 (0.00392) 19 (27.9) 2.6 (0.00457) 19 (27.9)
Dilated cardiomyopathy 2.3 (0.00489) 22 (24.7) 2.3 (0.00467) 22 (24.7)
Hypertrophic cardiomyopathy (HCM) 2.3 (0.00487) 21 (25.3) 2.2 (0.00904) 20 (24.1)
Aldosterone-regulated sodium reabsorption 2.8 (0.00761) 13 (31.0) 2.9 (0.00814) 13 (31.0)
Influenza A 1.7 (0.0308) 29 (18.4) 4.0 (0.000283) 13 (8.2)
Type II diabetes mellitus 2.5 (0.0185) 13 (27.7) 2.6 (0.0203) 13 (27.7)
Carbohydrate digestion and absorption 2.6 (0.0225) 12 (27.9) 2.4 (0.0474) 11 (25.6)
Type I diabetes mellitus 8.2 (0.000269) 7 (17.1)
Asthma 10.3 (0.000274) 6 (21.4)
Tuberculosis 3.8 (0.000386) 13 (7.9)
Antigen processing and presentation 5.7 (0.000668) 8 (11.9)
Phagosome 3.7 (0.00131) 11 (7.7)
Autoimmune thyroid disease 6.9 (0.00152) 6 (14.3)
Intestinal immune network for IgA production 6.3 (0.00233) 6 (13.0)
Chagas disease (American trypanosomiasis) 2.0 (0.0206) 22 (21.4)
Prion diseases 5.5 (0.0246) 4 (11.4)
African trypanosomiasis 2.6 (0.031) 10 (28.6)
KEGG pathways that are found as significantly enriched (q < 0.05) in three comparisons are shown. Eight pathways especially relevant to RA are placed in the
top part of the table. Within each section, the number of significant comparisons orders the pathways. If multiple pathways have the same number of
comparison then an average q values is used for ordering. # denotes the number of DMGs in the selected pathway.
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Table 3 Gene ontology terms that are enriched in two or more sets of genes
Comparison name Combined OA+NL OA or NL

















9 (19.1) 3.3 (0.00106) 17 (36.2)
proteinaceous extracellular matrix CC 2.2 (7.07e-
05)
48 (24.2) 3.3 (0.00287) 14 (7.1) 2.1
(0.000254)
46 (23.2)
signal transduction BP 1.4
(0.000717)
174 (15.4) 1.5 (0.0263) 37 (3.3) 1.4
(0.000713)
172 (15.2)
extracellular matrix CC 2.3 (0.00282) 30 (25.0) 2.3 (0.0441) 6 (5.0) 2.3 (0.00192) 30 (25.0)
inflammatory response BP 1.8 (0.00821) 45 (20.1) 2.3 (0.0301) 11 (4.9) 1.8 (0.0106) 44 (19.6)
fibroblast growth factor receptor signaling’ BP 9.1 (0.02) 4 (100.0) 23.5 (0.0176) 2 (50.0) 9.2 (0.0177) 4 (100.0)
MHC class II protein complex CC 4.5 (0.0346) 7 (50.0) 20.1 (9.47e-
05)
6 (42.9) 4.6 (0.0303) 7 (50.0)
focal adhesion CC 2.1 (0.0176) 26 (23.6) 2.6 (0.0418) 6 (5.5) 2.2 (0.0136) 26 (23.6)
Rho guanyl-nucleotide exchange factor activity MF 2.3 (0.0443) 18 (25.4) 3.3 (0.0375) 5 (7.0) 2.3 (0.0377) 18 (25.4)
regulation of Rho protein signal transduction BP 2.3 (0.0481) 18 (25.0) 3.3 (0.038) 5 (6.9) 2.3 (0.0412) 18 (25.0)
positive regulation of inflammatory response BP 3.3 (0.0173) 12 (36.4) 3.3 (0.0141) 12 (36.4)
cell adhesion BP 1.4 (0.0425) 84 (15.7) 1.4 (0.0404) 83 (15.5)
extracellular region CC 1.6 (2.4e-13) 306 (17.2) 1.8
(0.000356)
67 (3.8) 1.6 (4.11e-
13)
302 (16.9)




34 (4.6) 1.6 (7.7e-06) 130 (17.7)







plasma membrane CC 1.3 (4.6e-08) 467 (14.3) 1.4 (0.00269) 99 (3.0) 1.3 (6.35e-
08)
461 (14.1)
Z disc CC 3.5 (0.00133) 16 (38.1) 5.6 (0.0161) 5 (11.9) 3.5 (0.00099) 16 (38.1)
scavenger receptor activity MF 3.5 (0.00104) 16 (39.0) 4.6 (0.0327) 4 (9.8) 3.6
(0.000814)
16 (39.0)
odontogenesis BP 4.2 (0.00175) 12 (46.2) 5.4 (0.0374) 3 (11.5) 4.2 (0.00132) 12 (46.2)
integral to plasma membrane CC 1.4 (0.00501) 149 (15.2) 1.6 (0.0271) 33 (3.4) 1.4 (0.0102) 145 (14.8)
multicellular organismal development BP 1.5
(0.000606)
143 (16.1) 1.4 (0.0435) 27 (3.0) 1.5
(0.000332)
143 (16.1)
structural molecule activity MF 1.9 (0.00594) 42 (20.9) 2.1 (0.0414) 9 (4.5) 1.9 (0.0041) 42 (20.9)
positive regulation of cell proliferation BP 1.6 (0.019) 58 (17.8) 2.9 (0.00105) 20 (6.2) 1.6 (0.0315) 56 (17.2)
positive regulation of interferon-gamma
production
BP 3.2 (0.0439) 10 (35.7) 10.1
(0.00104)
6 (21.4) 3.3 (0.0383) 10 (35.7)
skeletal muscle contraction BP 5.5 (0.0292) 6 (60.0) 9.4 (0.0378) 2 (20.0) 5.5 (0.0256) 6 (60.0)
sarcolemma CC 2.5 (0.0352) 17 (27.0) 3.7 (0.0326) 5 (7.9) 2.5 (0.0296) 17 (27.0)
structural constituent of muscle MF 2.7 (0.0487) 13 (29.5) 4.3 (0.0353) 4 (9.1) 2.7 (0.0423) 13 (29.5)
actin binding MF 1.6 (0.0497) 49 (17.5) 2.0 (0.0373) 12 (4.3) 1.6 (0.0404) 49 (17.5)
myeloid cell differentiation BP 4.2 (0.0456) 7 (46.7) 6.3 (0.0434) 2 (13.3) 4.3 (0.0403) 7 (46.7)
sarcomere CC 3.3 (0.00145) 17 (36.2) 3.3 (0.00106) 17 (36.2)
skin morphogenesis BP 9.1 (0.0036) 5 (100.0) 9.2 (0.00292) 5 (100.0)
potassium channel regulator activity MF 3.8 (0.0172) 10 (41.7) 3.8 (0.0141) 10 (41.7)
response to organic cyclic compound BP 2.2 (0.0177) 25 (24.0) 3.2 (0.0274) 7 (6.7)
response to mechanical stimulus BP 2.8 (0.0383) 13 (31.0) 5.6 (0.0161) 5 (11.9)
response to glucocorticoid stimulus BP 2.3 (0.0306) 20 (25.3) 3.6 (0.0273) 6 (7.6)
response to prostaglandin E stimulus BP 6.5 (0.0313) 5 (71.4) 6.6 (0.0277) 5 (71.4)
regulation of muscle contraction BP 5.0 (0.0433) 6 (54.5) 5.0 (0.0383) 6 (54.5)
epidermis development BP 2.2 (0.0448) 19 (24.7) 3.0 (0.0402) 5 (6.5)
ion transport BP 1.4 (0.0437) 84 (15.7) 1.4 (0.0415) 83 (15.5)
PR of GMSFP’ BP 7.3 (0.0493) 4 (80.0) 7.4 (0.0441) 4 (80.0)
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pathway (see Figure 5) is 1.89-fold enriched (P = 0.0042
and q = 0.0377) with 19 out of 92 genes labeled as
DMGs in the union set.
Certain KEGG pathways and GO categories are signifi-
cantly enriched in ‘OA+NL’ or ‘OA or NL’ but are not sig-
nificantly enriched in ‘combined’. This can occur because
the increase in the total number of significant genes can
affect the enrichment of a subset of genes within a particu-
lar pathway. For example, the KEGG pathway ‘cytosolic
DNA sensing’ is significantly enriched in ‘OA+NL’ but not
in combined despite the ‘OA+NL’ containing five DMGs
in the pathway whereas ‘combined’ contains eight. This
occurs because the total number of DMGs increases from
472 in ‘OA+NL’ to 2,375 in ‘combined’.
Determination of differentially methylated GO pathways
in RA FLS
The enriched GO categories out of the full 34,449 cate-
gory dataset are summarized in Table 4 where 10
categories especially relevant to RA are listed at the top
of the table. Of particular interest is the overlap with
KEGG because of the preponderance of matrix, adhe-
sion, and signaling GO categories.
Discussion
Fibroblast-like synoviocytes (FLS), which form the syno-
vial intimal lining, play an integral role in the pathogen-
esis of RA by producing cytokines, small molecule
mediators, and proteases [1]. The FLS are responsible
for cartilage damage by virtue of their ability to adhere
to and invade the cartilage extracellular matrix [11].
Rheumatoid FLS exhibit a unique aggressive phenotype
that contributes to the cytokine milieu and joint
destruction [12]. Functional studies suggest that RA
cells are imprinted in situ and maintain these features
after many passages in tissue culture. For example, RA
FLS, unlike OA or NL synoviocytes, invade cartilage
explants in SCID mice [13]. RA FLS can grow under
Table 3 Gene ontology terms that are enriched in two or more sets of genes (Continued)
troponin complex CC 5.7 (0.0495) 5 (62.5) 5.7 (0.0442) 5 (62.5)
phosphatase binding MF 5.7 (0.0495) 5 (62.5) 5.7 (0.0442) 5 (62.5)
GO categories that are significantly enriched (q < 0.05) during three comparisons are shown. Twelve pathways especially relevant to RA are placed in the top part of the
table while other pathways are show at the bottom. Within each section, the number of significant comparisons orders the pathways. If multiple GO categories are
significantly enriched in the same number of comparison then an average q values is used for ordering. Only GO categories found as significantly enriched in three or
more comparisons are shown. # denotes the number of DMGs in the selected pathway. The GO category ‘positive regulation of granulocyte macrophage colony-
stimulating factor production’ is abbreviated to ‘PR of GMSFP’ and category ‘regulation of fibroblast growth factor receptor signaling pathway’ is abbreviated to ‘fibroblast
growth factor receptor signaling’. The GO types stand for: BP: biological process; CC: cellular component; MF: molecular function.
Figure 2 DMGs in the KEGG RA pathway. The methylation status at the promoters of genes within the pathway is shown. The coloring
scheme is as follows: yellow are hyper-methylated in RA, blue are hypo-methylated in RA, pink contain both hyper and hypo loci in their
promoters, and green contain no significantly DML in their promoters.
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anchorage-independent conditions, are less susceptible
to contact inhibition, and resistant to apoptosis [14,15].
DNA methylation could play a critical role in joint
damage by epigenetic imprinting FLS in RA. Evidence of
abnormal methylation and a distinct methylation signa-
ture was recently described in RA synoviocytes [6]. Using
a limited number of cell lines, hyper- and hypomethy-
lated CpG sites were demonstrated in nearly 2,000 loci
located in 1,200 genes. Methylation status determined by
array analysis was confirmed by bisulfite sequencing and
correlated with gene expression in that study. Additional
analysis identified over 200 genes with multiple differen-
tially methylated loci. Preliminary KEGG and GO analy-
sis suggested that pathways involved with inflammation,
matrix regulation, and immune responses are differen-
tially methylated. The present study greatly expands
upon the initial dataset by doubling the number of RA
and OA FLS and adding normal FLS. The increased
Figure 3 DMGs in the KEGG ‘Complement and coagulation cascades’ pathway. The methylation status at the promoters of genes within
the pathway is shown. The coloring scheme is as follows: yellow are hyper-methylated in RA, blue are hypo-methylated in RA, pink contain
both hyper and hypo loci in their promoters, and green contain no significantly DML in their promoters.
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sample size also allowed us to focus our analysis on dif-
ferentially methylated promoter sites. These data refined
the KEGG and GO analysis and led to identification of
additional key pathways implicated in disease.
Before extending our computational studies, we deter-
mined if the RA methylation signature is stable. Compari-
son of the methylation patterns between different passages
of RA, OA, and NL FLS showed that the signature changes
very little over time. These results correlate with previous
studies demonstrating that the FLS transcriptome is also
stable in culture [2,16]. By the 7th passage, a slight
increase in methylation variability was detected, but the
correlation was only slightly lower than between replicates
of the same passage. Furthermore, the most significant
methylation changes that may be associated with patho-
genic processes appear to be very stable over time in FLS
lines. These data suggest that the majority of the variation
is a result of noise in the bead array assay.
Methylome stability has been observed with other long-
term cultured cell lines. For instance, multiple passages
of the cell lines IMR90 (human fetal lung fibroblast) and
H1 (human embryonic stem cells) showed high concor-
dance [17]. The methylome is not immutable, however,
and can be modulated by the environment, different
developmental stages [18], or prolonged tissue culture
[19]. For example, dynamic changes in methylome occur
in human embryonic stem cells, a fibroblastic differen-
tiated derivative of the human embryonic stem cells, and
neonatal fibroblasts. Immortalized fibroblasts that evolve
separately over 300 generations show stochastic methyla-
tion changes. Despite the random nature of changes, they
resulted in a deterministic remodeling of the methylome
that correlates with histone modification and CTCF
binding.
The stability of the RA methylome signature from the
earliest possible passage (P3) to cells approaching senes-
cence (P7) suggests that it is imprinted in FLS rather than
a transient phenomenon. However, it does not tell us the
origin of the RA methylome signature. In particular, we
are still unsure whether the imprinting predates disease, is
brought about by interaction with the pre-RA synovium
environment, or is modified by RA in a way that influences
the behavior of FLS. Our recent study show that DNMT
expression and function are suppressed in FLS when
exposed to IL-1 [20]. However, this effect is transient and
is reversed 2 weeks after the cytokine is removed from the
cultures. Therefore, cytokines can potentially contribute to
altered DNA methylation in FLS but probably do not
Figure 4 DMGs in the KEGG ‘Focal Adhesion’ pathway. The methylation status at the promoters of genes within the pathway is shown. The
coloring scheme is as follows: yellow are hyper-methylated in RA, blue are hypo-methylated in RA, and green contain no significantly DML in
their promoters. Note that the following extracellular matrix (ECM) genes not specified in the figure are hypo-methylated: COL1A1, COL1A2,
COL2A1, COMP, LAMA2, LAMB3, and VWF.
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account for the long-lasting effects. Evaluation of FLS
from patients at high risk for RA but without clinical dis-
ease would be needed to resolve this issue with greater
certainty. Also, specificity for RA, as opposed to other
forms of inflammatory arthritis, will require evaluation of
FLS from other forms of synovitis.
Systems level analysis of the RA methylome signature
in our expanded dataset reveals that DMLs are highly
enriched in the promoters of genes that belong to char-
acteristic functional categories. Because we had three
distinct cell populations, we used several different ways
to evaluate how RA differed from OA and/or NL FLS.
There were some differences in the genes and pathways
that were differentially methylated depending on how
the phenotypes were grouped. Relatively broad agree-
ment among the various types of analyses was observed.
The most gratifying was the RA pathway in the KEGG
analysis, which was found in the three most robust com-
parisons and confirmed the relevance of our analysis to
this disease.
We also found the enrichment of many pathways that
are related to the RA phenotype and immune responses.
The KEGG and GO analysis of differentially methylated
pathways is, therefore, non-random and likely essential for
establishment or maintenance of the RA FLS phenotype.
Even many of the seemingly less relevant categories that
were identified as enriched result from overlap in sets of
genes that are shared with pathways that are more clearly
relevant to RA. For example, the pathway ‘Staphylococcus
aureus infection’ contains 16 DMGs; however, six of these
are also present in the RA pathway.
The nature of the RA-associated pathways enriched in
our KEGG and GO analysis provides clues regarding the
pathogenesis of the disease. For example, the role of
complement is well documented in animal studies [21].
This innate immune mechanism is also strongly impli-
cated in the initiation and acute inflammatory reaction
of RA [22]. Several complement components are pro-
duced by FLS in the intimal lining as well as cultured
synoviocytes [23]. The pathway analysis indicates that
regulation of complement is abnormal in addition to the
fact that it is robustly consumed in the joints.
Altered methylation and, presumably, gene regulation
in FLS is also observed for many other components of
innate immunity. Notably, TLR, cytosolic DNA-sensing,
and NOD-like receptor pathways are significantly
enriched in the KEGG analysis for differentially methy-
lated genes. Each pathway has been implicated as funda-
mental mechanisms that regulate the inflammatory
response in RA [24-26]. Genes regulating innate immu-
nity are emerging as potential therapeutic targets for RA,
and the methylation data supports their participation in
Figure 5 DMGs in the KEGG ‘Toll-like receptor signaling’ pathway. The methylation status at the promoters of genes within the pathway is
shown. The coloring scheme is as follows: yellow are hyper-methylated in RA, blue are hypo-methylated in RA and green contain no
significantly DML in their promoters.
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rheumatoid synovitis. Similarly, multiple cytokines are
differentially methylated in the RA pathway and in the
cytokine-cytokine receptor pathway, including TNF and
other critical mediators of RA. Additional types of path-
ways involving inflammation, host defense, and immune
responses are enriched in the GO analysis and are consis-
tent with the insights gleaned from the KEGG pathways.
The data suggest that pathway analysis can provide
other clues for disease pathogenesis and novel therapeutic
interventions. For example, cell-cell and cell-matrix inter-
actions are differentially methylated in the focal adhesion
pathway and the cell adhesion molecule pathways. Several
potential therapeutic targets are within these pathways
and could be explored for diseases like RA. The specific
genes that are differentially methylated are not necessarily
the ones that should be the focus of drug development.
Instead, more attractive proteins in the pathway that are
more amenable to inhibition or modulation could be
selected and achieve the same result.
Conclusions
An expanded dataset evaluating differentially methylated
pathways confirmed the limited data and greatly extended
the number of pathways that are enriched in RA. The rela-
tive stability of the signature was also demonstrated, sup-
porting the notion that the cells are imprinted rather than
merely reflecting transient cytokine effects. These data can
provide insights into the pathogenesis of RA as well as
identifying potential therapeutic targets.
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